Description
Semaglutide Oral is the oral tablet variant of the well-known GLP-1 receptor agonist Semaglutide. Clinically the oral variant is approved under the brand name Rybelsus; the same active ingredient is administered subcutaneously under the brand names Ozempic (diabetes) and Wegovy (obesity).
Per study reports Semaglutide activates the GLP-1 receptor in the pancreas (insulin secretion), stomach (delayed emptying), and hypothalamus (satiety). The consequence is decreased food intake, slowed gastric passage, and in the diabetes model an improved glucose profile. In the landmark STEP 1 study (Wilding et al 2021, NEJM) subjects with subcutaneous Semaglutide achieved 14.9% weight loss over 68 weeks.
The oral variant has a decisive challenge: GLP-1 peptides are degraded enzymatically in the gastrointestinal tract. Semaglutide Oral is therefore co-formulated with SNAC (sodium salcaprozate), an absorption enhancer that enables uptake at the gastric mucosa. Bioavailability remains low at about 1% - that’s why oral doses are much higher (7-25mg) than subcutaneous (0.5-2.4mg).
Important intake requirements: fasting, with max 120ml still water, then wait at least 30 minutes before eating or other medications. If this is violated, bioavailability drops further.
Known effects in studies: nausea (especially at start, usually subsides after 4-6 weeks), vomiting, diarrhea, rarely pancreatitis. Thyroid C-cell tumors documented in rats - clinical relevance in humans disputed.
You can order Semaglutide Oral as tablets in one bottle with 3mg or 7mg per tablet.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
Semaglutide Oral contains the same GLP-1 active ingredient as the subcutaneous form, so the documented profile is correspondingly dominated by gastrointestinal effects. The oral tablet form additionally carries strict intake requirements.
Observed in studies and user reports:
- Gastrointestinal effects: nausea, vomiting, diarrhea and constipation are the most commonly documented observations, particularly at the start, and in studies usually subside after 4-6 weeks. Slow titration reduces the incidence.
- Appetite and fluids: the reduced appetite can lead to decreased food and fluid intake, and the literature describes an elevated risk of dehydration.
- Muscle mass and gallbladder: weight loss involves a portion of muscle mass alongside fat mass, and gallbladder issues during rapid weight loss are documented.
- Pancreas and thyroid: in rarer cases pancreatitis is documented, and thyroid C-cell tumors were observed in rats, whose relevance in humans is disputed.
- Strict intake requirements: bioavailability is only around 1 percent, and any deviation from fasting intake lowers it further.
Monitoring via bloodwork is recommended. This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- Oral Semaglutide versus Subcutaneous Liraglutide in Type 2 Diabetes (PIONEER 4) - Lancet 2019, Pratley et al: Direct comparison RCT between oral and subcutaneous form.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) - NEJM 2021, Wilding et al: Gold standard obesity treatment study.
- PIONEER 6 - Oral semaglutide and cardiovascular outcomes in type 2 diabetes - NEJM 2019, Husain et al: Cardiovascular safety study on oral variant.
